Abstract
This research service covers the Anti-obesity Prescription Markets across the United States for the perios 2002 through 2012.
The research service provides a detailed analysis of the revenue structure across therapies. Strategic recommendations for these have also been discussed along with revenue forecasts.
Table of Contents
1. EXECUTIVE SUMMARY
Executive Summary
- 1. Introduction
2. INTRODUCTION TO U.S. ANTI-OBESITY PRESCRIPTION MARKETS
Introduction
- 1. Market Overview
- 2. Research Scope and Methodology
Basic Obesity Terminologies and Definitions
- 1. Obesity Definition
- 2. Obesity Classification
- 3. Obesity Etiology
- 4. Obesity Diagnosis
Market Dynamics
- 1. Analysis
- 2. Market Drivers
- 3. Market Restraints
- 4. Market Trends
Industry Challenges and Strategic Recommendations
- 1. Industry Challenges
- 2. Strategic Recommendations
Frost & Sullivan Awards
- 1. Industry Innovation and Advancement of the Year
- 2. Technology Innovation of the Year Award
- 3. Product Differentiation Innovation of the Year Award
3. MARKET SEGMENTATION
Disease and Treatment Overview
- 1. Obesity Prevalence Forecasts
- 2. Obesity Diagnosed and Treated Patient Forecasts
- 3. Obesity Patient Compliance
- 4. Obesity Comorbid Conditions
- 5. Unmet Needs in Obesity
Product Analysis
- 1. Overview of Marketed Products
- 2. Xenical and Meridia SWOT Analyses
- 3. Key Patent Expirations
Competitive and Pipeline Analysis
- 1. Competitive Landscape
- 2. Competitor Profiles
- 3. Pipeline Analysis
- 4. Anticipated Launch Dates
- 5. Alliances Acquisitions and Licensing Agreements
Market Forecasts
- 1. Revenue Forecasts and Assumptions
- 2. Pricing Trends
- 3. Market Share Analysis
4. APPENDIX
Decision Support Databases
- 1. Total Population
- 2. Prevalence of Diabetes Mellitus
- 3. Diabetes Incidence
- 4. Prevalence of Obesity
- 5. Mortality Due to Coronary Heart Disease
